TY - JOUR
T1 - Positron emission tomographic scans in lymphoma
T2 - Convention and controversy
AU - Ansell, Stephen M.
AU - Armitage, James O.
N1 - Funding Information:
Potential Competing Interests: Dr Armitage reports consultant or advisory boards roles with Ziopharm, Seattle Genetics, Genentech, Allos, and Roche. Dr Ansell reports research funding from Seattle Genetics.
PY - 2012/6
Y1 - 2012/6
N2 - The use of sensitive and specific imaging techniques for accurate initial staging and evaluation of response to therapy in patients with lymphoma is essential for their optimal management. Fluorine 18 fluorodeoxyglucose (FDG) positron emission tomography (PET) integrated with computed tomography (CT) has emerged as a powerful imaging tool and is being routinely used in staging, response evaluation, and posttreatment surveillance in patients with non-Hodgkin lymphoma and Hodgkin lymphoma. PET/CT is currently widely used in clinical practice, but the established clinical benefit is currently restricted to the posttreatment evaluation of Hodgkin lymphoma, diffuse large B-cell lymphoma, and follicular lymphoma. Although used in other histologic subtypes and in other clinical situations including response assessment, its impact on patient outcome remains to be demonstrated. We performed a literature search of PubMed from 1999 to 2011 using the following keywords: PET scan, FDG-PET, PET/CT, lymphoma. This review addresses the challenges and controversies in the use of PET/CT scans in the management of patients with lymphoma.
AB - The use of sensitive and specific imaging techniques for accurate initial staging and evaluation of response to therapy in patients with lymphoma is essential for their optimal management. Fluorine 18 fluorodeoxyglucose (FDG) positron emission tomography (PET) integrated with computed tomography (CT) has emerged as a powerful imaging tool and is being routinely used in staging, response evaluation, and posttreatment surveillance in patients with non-Hodgkin lymphoma and Hodgkin lymphoma. PET/CT is currently widely used in clinical practice, but the established clinical benefit is currently restricted to the posttreatment evaluation of Hodgkin lymphoma, diffuse large B-cell lymphoma, and follicular lymphoma. Although used in other histologic subtypes and in other clinical situations including response assessment, its impact on patient outcome remains to be demonstrated. We performed a literature search of PubMed from 1999 to 2011 using the following keywords: PET scan, FDG-PET, PET/CT, lymphoma. This review addresses the challenges and controversies in the use of PET/CT scans in the management of patients with lymphoma.
UR - http://www.scopus.com/inward/record.url?scp=84863457697&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84863457697&partnerID=8YFLogxK
U2 - 10.1016/j.mayocp.2012.03.006
DO - 10.1016/j.mayocp.2012.03.006
M3 - Article
C2 - 22677077
AN - SCOPUS:84863457697
SN - 0025-6196
VL - 87
SP - 571
EP - 580
JO - Mayo Clinic proceedings
JF - Mayo Clinic proceedings
IS - 6
ER -